ArticleFrontiers in oncology2019
Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- High-MannoseJournal of proteome research · 2026Article
- Collision-Induced Fragmentation of Oligosaccharides: Mechanistic Insights for Mass Spectrometry-Based Glycomics.Angewandte Chemie (International ed. in English) · 2025Review
- Glycosylation in Cancer.Handbook of experimental pharmacology · 2025Review
- Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.British journal of cancer · 2024Article
- Medical Relevance, State-of-the-Art and Perspectives of "Sweet Metacode" in Liquid Biopsy Approaches.Diagnostics (Basel, Switzerland) · 2024Review
- Noninvasive serum N-glycans associated with ovarian cancer diagnosis and precancerous lesion prediction.Journal of ovarian research · 2024Article
- N-glycan profiling of tissue samples to aid breast cancer subtyping.Scientific reports · 2024Article
- Research progress on m6A demethylase FTO and its role in gynecological tumors.Frontiers in oncology · 2024Review
- Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.Frontiers in endocrinology · 2024Review
- Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers.Science advances · 2023Article
- Toward Automatic Inference of Glycan Linkages Using MSJournal of the American Society for Mass Spectrometry · 2023Article
- Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer.Proteomics. Clinical applications · 2023Article
- The diagnostic effectiveness of serum sialic acid predicts both qualitative and quantitative prostate cancer in patients with prostate-specific antigen between 4 and 20 ng/mL.Frontiers in endocrinology · 2023Article
- In SituCancers · 2022Article
- Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment.International journal of cancer · 2022Review
- Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Glycomic-Based Biomarkers for Ovarian Cancer: Advances and Challenges.Diagnostics (Basel, Switzerland) · 2021Review
- In-House Packed Porous Graphitic Carbon Columns for Liquid Chromatography-Mass Spectrometry Analysis ofFrontiers in chemistry · 2021Article
- Isomer-Specific Monitoring of SialylatedFrontiers in molecular biosciences · 2021Article
- Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (EOC) is a rather rare but lethal disease that is usually diagnosed at an advanced stage; this is due to a lack of early diagnostic markers. At the time being, less than a quarter of patients are diagnosed when the tumor has not metastasized yet. In previous work, we demonstrated that antennarity, fucosylation, and sialylation increased in EOC patients and built a glycan-based score that was able to diagnose EOC better than CA125, the routine diagnostic marker, does. To date, little attention had been paid to the sialic acid linkages of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.